Moment-to-moment adjustment of cerebral blood flow (CBF) via neurovascular coupling has an essential role in maintenance of healthy cognitive function. In advanced age, increased oxidative stress and cerebromicrovascular endothelial dysfunction impair neurovascular coupling, likely contributing to age-related decline of higher cortical functions. There is increasing evidence showing that mitochondrial oxidative stress plays a critical role in a range of age-related cellular impairments, but its role in neurovascular uncoupling remains unexplored. This study was designed to test the hypothesis that attenuation of mitochondrial oxidative stress may exert beneficial effects on neurovascular coupling responses in aging. To test this hypothesis, 24-month-old C57BL/6 mice were treated with a cell-permeable, mitochondria-targeted antioxidant peptide (SS-31; 10 mg kg À1 day À1 , i.p.) or vehicle for 2 weeks.
age, increased oxidative stress and cerebromicrovascular endothelial dysfunction impair neurovascular coupling, likely contributing to age-related decline of higher cortical functions. There is increasing evidence showing that mitochondrial oxidative stress plays a critical role in a range of age-related cellular impairments, but its role in neurovascular uncoupling remains unexplored. This study was designed to test the hypothesis that attenuation of mitochondrial oxidative stress may exert beneficial effects on neurovascular coupling responses in aging. To test this hypothesis, 24-month-old C57BL/6 mice were treated with a cell-permeable, mitochondria-targeted antioxidant peptide (SS-31; 10 mg kg À1 day À1 , i.p.) or vehicle for 2 weeks. There is an increasing appreciation that (micro)vascular contributions to cognitive impairment and dementia in elderly patients are critical (Tarantini, Tran, Gordon, Ungvari & Csiszar, 2016) . Importantly, neurovascular coupling responses are impaired both in elderly patients (Fabiani et al., 2013; Stefanova et al., 2013; Topcuoglu, Aydin & Saka, 2009; Zaletel, Strucl, Pretnar-Oblak & Zvan, 2005) and aged laboratory animals (Park, Anrather, Girouard, Zhou & Iadecola, 2007; Toth et al., 2014) , which likely contributes significantly to the progressive age-related decline in higher cortical function, including cognition (Sorond, Hurwitz, Salat, Greve & Fisher, 2013) and gait coordination (Sorond et al., 2011) . Experimental studies support this concept, showing that pharmacologically induced neurovascular uncoupling in mice mimics important aspects of age-related cognitive impairment . On the basis of these findings, we proposed that novel therapeutic interventions should be developed to rescue functional hyperemia in elderly patients to prevent/delay cognitive impairment (Toth et al., 2014) .
There is strong evidence that microvascular endothelial NO synthesis/release is stimulated during increased neuronal activity (via ATP-mediated activation of endothelial purinergic receptors), which critically contribute to functional hyperemia under normal conditions (Toth, Tarantini, Davila et al., 2015) . Previous studies demonstrate that aging exacerbates generation of reactive oxygen species (ROS) in the cerebromicrovascular endothelial cells, which contribute to age-related neurovascular uncoupling in aged mice by promoting endothelial dysfunction (Toth et al., 2014) . We hypothesize that pharmacological treatments, which attenuate endothelial oxidative stress and rescue NO mediation, will have the capacity to improve neurovascular coupling in aged individuals.
The mitochondrial free radical theory of aging posits that mitochondria-derived ROS (mtROS) production and related mitochondrial dysfunction are a critical driving force in the aging process. In support of this theory, it was demonstrated that attenuation of mitochondrial oxidative stress (by mitochondria-targeted overexpression of catalase) increases mouse lifespan (Schriner & Linford, 2006) . Further, pharmacological treatments that attenuate mtROS production were shown to counteract some of the effects of aging in skeletal muscle (Siegel et al., 2013) and the heart (Dai, Chiao, Marcinek, Szeto & Rabinovitch, 2014; Dai, Rabinovitch & Ungvari, 2012; Dai et al., 2011) . There is particularly strong evidence that mitochondrial oxidative stress is implicated in cardiovascular aging processes (Dai et al., 2012; Springo et al., 2015) . Yet, although drugs that improve mitochondrial function have been shown to exert beneficial effects both on the vasomotor function of peripheral arteries (Gioscia-Ryan et al., 2014; Pearson et al., 2008) , their potential protective effects on the aged cerebral microvasculature has not been investigated.
This study was designed to test the hypothesis that pharmacological attenuation of mtROS can restore cerebromicrovascular endothelial function and thus improve neurovascular coupling in aged mice. To achieve this goal, in aged mice mitochondrial oxidative stress was manipulated by treatment with the mitochondrial-targeted Szeto-Schiller (SS) peptide SS-31. SS-31 is a tetrapeptide with alternating aromatic-cationic amino acid motif (H-D-Arg-Dmt-Lys-Phe-NH 2 ), which concentrates in the inner mitochondrial membrane more than 1,000-fold compared with the cytosolic concentration (Bakeeva et al., 2008; Doughan & Dikalov, 2007; Zhao et al., 2004) and is able to effectively reduce levels of O 2 À , H 2 O 2, hydroxyl radical and peroxynitrite both in vitro and in vivo (Graham et al., 2009; Szeto, 2008; Zhao et al., 2004 Treatment of aged mice with SS-31 significantly improved both acetylcholine-and ATP-induced vasodilation, restoring responses to the level observed in vessels of young mice. To assess the role of endothelium-derived NO, L-NAME was applied. L-NAME significantly inhibited acetylcholine-and ATP-induced dilator responses, eliminating the differences between the three groups. we assessed the effects of SS-31 on cellular mtROS production in cultured CMVECs derived from aged animals using the MitoSox fluorescence method. We found that mtROS production in CMVECs derived from aged animals was significantly increased as compared to that in CMVECs derived from young animals ( Figure 2f ). SS-31 treatment elicited significant decreases in mtROS production in aged CMVECs, eliminating the difference between the two age groups Previous studies show that selective pharmacologically induced neurovascular uncoupling is associated with cognitive impairment . To determine how restoration of cerebromicrovascular function impacts cognitive function in aged mice, animals were tested in the radial-arm water maze ( Figure 3a) . We compared the learning performance of mice in each experimental group by analyzing the day-to-day changes in the combined error rate, successful escape rate, degree of divergence, path length, and time latency.
During acquisition, mice from all groups showed a decrease in the combined error rate ( Figure 3b ) across days, indicating learning of the task. After the first day of learning, young mice consistently had lower combined error rate than aged mice ( Figure 3b ). Treatment with SS-31 did not alter the combined error rate in aged mice.
To analyze working memory function (short-term memory that is involved in immediate conscious perception), we examined re-entries into incorrect arms (without hidden platform) that were previously attempted for escape. We found that working memory function was impaired in aged mice as compared to young controls ( Figure 3c ).
Aged mice that were treated with SS-31 showed significant restoration of working memory to levels comparable to young animals ( Figure 3c ). SS-31 treatment thus resulted in a marked improvement in working memory while there was no clear effect of SS-31 on learning.
Successful escape rate from the maze was assessed by measuring the percent of animals that could find the hidden platform within the 60 s allowed for each trial. During acquisition, mice from all groups showed an increase in successful escape rate consistent with the learning of the task. Young mice exhibited significantly better escape success than untreated aged mice (Figure 3d ). SS-31 treatment significantly increased the successful escape rate in aged mice, restoring it to the level observed in young mice (Figure 3d ). We attribute, at least in part, the higher successful escape rate in young maze-na€ ıve mice and SS-31-treated aged maze-na€ ıve mice to the more effective search strategy they used as indicated by the lower degree of divergence.
We also compared path length (i.e., the distance that the mouse swam between maze entry and successful escape through the hid- Older animals have higher combined error rates throughout days 2 and 3 of the learning phase and retrieval day 10 (p < .0001). Combined error rate is calculated by adding 1 error for each incorrect arm entry as well as for every 15 s spent not exploring the arms. Panel c: Older animals make significantly more working memory errors (repetitive incorrect arm entries) as compared to young mice. In contrast, aged mice treated with SS-31 perform this task significantly better than untreated aged mice (p = .04). Panel d: The ratio of successful escapes, averaged across trial blocks, is shown for each group. Note day-to-day improvement in the performance of young mice, which was significantly delayed in aged mice. Aged mice treated with SS-31 were more successful at finding the hidden escape platform in comparison with untreated age-matched controls (p < .0001). Panel e: Average path length required to reach the hidden platform in the RAWM for trial blocks 1-6 and for probe trial on day 10. Young mice find the hidden platform while swimming significantly less than aged animals (p < .0001). In aged mice treated with SS-31, the average path length required to reach the hidden platform did not differ from that in young mice. Panel f: Escape latencies to find the hidden platform in the RAWM for aged control mice are significantly higher when compared to young and aged treated mice (p < .0001 for both comparisons). Panel g: There was no significant difference in swimming speed among all experimental groups. Panel h: SS-31 treatment reduced the time spent engaged in nonexploratory behavior in control-treated old mice as compared to young animals. (p < .0001). n = 20 in each group. All data are shown as mean AE SEM. Statistical significance was calculated using one-way ANOVA with Tukey's post hoc test to determine differences among groups (Figure 3f ) than untreated aged mice, which differences remained pronounced on day 3 of acquisition and the probe trial. In contrast, in aged mice treated with SS-31 path length and escape latencies were similar to that observed in young mice (Figure 3e,f) . The analyses of noncognitive parameters revealed no difference in swimming speed and only a slight, age-dependent increase in nonexploratory behavior (the cumulative time the mice spent not actively looking for the platform, e.g., floating), which was reduced in SS-31-treated animals (Figure 3g,h ). Taken together, the aforementioned results suggest that in aged mice SS-31 treatment improved performance in the radial-arm water maze, which results from enhanced hippocampal-dependent spatial learning and memory and not from changes in motor or motivational processes.
| Treatment with SS-31 restores motor learning function in aged mice
To investigate the effects of age and SS-31 treatment on the motor performance of mice, we measured grip strength and inverted grid hang time (data not shown), which evaluates muscle strength and endurance. We found that neither aging nor SS-31 treatment affected the outcome of these tests.
Motor skill learning was assessed using a modified rotarod test.
During a 4-day-long experimental period, young mice displayed a steeper motor skill learning curve compared to aged control mice.
After the first day, aged control animals consistently fell off the accelerating rotarod earlier compared to young controls, showing impaired acquisition of motor skill learning. Treatment with SS-31 restored motor skill learning behavior to the young control levels ( Figure 4a ).
| Treatment with SS-31 does not restore gait function in aged mice
Age-related deficiencies in neurovascular coupling responses in human patients have been linked to gait abnormalities (Sorond et al., 2011) . To identify subtle age-and treatment-related differences between mouse gait patterns, principal component analysis (PCA) was carried out on the correlation matrix of averages of spatial and temporal indices of gait. This analysis identified three principal components that accounted for~68% of the variance in the data. We plotted the position of each mouse against the PC1, PC2, and PC3 axes in three-dimensional space (Figure 4b ). The most conspicuous trend was that young and aged mice appeared well separated along F I G U R E 4 SS-31 treatment in aged mice improves motor skill learning but not gait coordination. a) Motor skill learning on the accelerating rotarod. Daily changes in mean latencies to fall for young (3 months old), aged (24 months old) and SS-31-treated aged mice are shown. Data are mean AE SEM. (n = 20 in each group). *p < .05 vs. young control; # p < .05 vs. aged control. b) 3D triplot of first three principal components (PC) identified by PCA on the correlation matrix of spatial and temporal indices of gait. Each point represents an individual mouse, and centroids are shown for each experimental group. Note that mice in the same age groups clustered together. Distance between centroids is shown inset. Whole differences between young and aged mouse gait were evident, rescue of NVC responses by SS-31 treatment did not reverse age-related changes in mouse gait (MANOVA; p = .47 aged vs. aged treated; p < .001 young vs. aged; p < .0001 young vs. aged treated). c) Scheme showing proposed role for increased mitochondrial oxidative stress in cerebromicrovascular endothelial impairment and neurovascular dysfunction in aging the PC2 and PC3 axes. In contrast, aged mice and SS-31-treated aged mice were clustered together.
| DISCUSSION
The key finding of his study is that the mitochondria-targeted antioxidative peptide SS-31 exerts significant beneficial effects on neurovascular coupling responses and cognitive function in a mouse model of aging that recapitulates cerebromicrovascular dysfunction and deficits of higher brain function manifested in elderly patients.
Extending previous findings in elderly patients and aged laboratory animals, we demonstrate that aging leads to significant neurovascular dysregulation in mice, characterized by diminished CBF changes in response to increased neuronal activity (Figure 1) . Here, we demonstrate for the first time that aging-induced decline in neurovascular coupling is restored by treatment with SS-31 ( Figure 1 ).
There is strong experimental evidence that endothelial NO production contributes importantly to neurovascular coupling (Toth et al., 2014) . This concept is supported by our observation that both genetic depletion of eNOS (Toth, Tarantini, Davila et al., 2015) and The mechanisms by which SS-31 attenuates mtROS production in aging are likely multifaceted. Age-related loss of efficiency in mitochondrial electron transport likely increases electron leak and mtROS production. SS-31 is known to concentrate in the inner mitochondrial membrane more than 1,000-fold compared with the cytosolic concentration (Bakeeva et al., 2008; Doughan & Dikalov, 2007; Zhao et al., 2004) . While SS-31 may scavenge ROS directly at the site of their production, recent studies show that SS-31 binds to cardiolipin via electrostatic and hydrophobic interactions and thereby protects the structure of mitochondrial cristae, increasing the efficiency of mitochondrial electron transport (Siegel et al., 2013) and attenuating mtROS production (Szeto, 2014) . Increased efficiency of ATP generation and reduction in ROS are thereby coupled. Based on the findings that SS-31 improves mitochondrial respiration in cerebromicrovascular endothelial cells (Figure 2h ), while reducing ROS generation (Figure 2f ,g) we posit that such a mechanism is operational in the cerebral microcirculation of SS-31-treated aged mice.
There are studies suggesting that upregulation of the tissue reninangiotensin II system (Wang et al., 2007) contributes to increased vascular oxidative stress in aging (Modrick, Didion, Sigmund & Faraci, 2009 ). Importantly, SS-31 was also shown to effectively attenuate angiotensin II-induced mtROS production (Dai et al., 2011) . The microvascular endothelium in the brain, which maintains the bloodbrain barrier and exhibits controlled transcellular transport systems, has high energy demands. Future studies should determine how SS-31-induced changes in cellular energetics impact barrier and transport function in aged CMVECs. In addition, there is growing evidence that mitochondria-derived ROS regulate the expression and activity of plasma membrane-associated NADPH oxidases in vascular cells (reviewed in Dai et al. (2012) ). Accordingly, in the cerebral circulation of aged mice increased mitochondrial oxidative stress is associated with an upregulated expression and activity of NADPH oxidases (Park et al., 2007; Toth et al., 2014) , which appear to be partially reversed by SS-31 (Figure 2i ) as well as by other interventions that attenuate mtROS production in aging (Toth et al., 2014) .
Interestingly, SS-31-induced downregulation of NADPH oxidases has also been observed previously in the heart (Dai et al., 2011 ) and the kidney (Hou et al., 2016) . Thus, we posit that SS-31 may also alter the interplay between mitochondria and NADPH oxidases, disrupting a vicious feed-forward cycle that diminishes NO bioavailability and promotes neurovascular uncoupling. Furthermore, one can hypothesize that SS-31 treatment of aged mice may also attenuate astrocyte-derived ROS generation, in addition to its beneficial endothelial effects, thereby improving astrocyte-mediated neurovascular coupling responses (e.g., by decreasing production of constrictor arachidonic acid metabolites). This possibility should be tested in future studies.
There is a growing appreciation of vascular contributions to cognitive decline and dementia. Importantly, clinical studies suggest that impairment of NVC responses contributes to the age-related decline in higher cortical functions (Sorond et al., 2011 (Sorond et al., , 2013 ). Recent studies demonstrate that BOLD signal is positively correlated with working memory in rodent models and that impaired memory is associated with impaired NVC (reduced BOLD activity) in the hippocampus (Febo & Foster, 2016) . Our recent studies provide strong experimental evidence in support of this concept, demonstrating that impairment of NVC responses and cognitive decline in mice are causally related . The present study is the first to demonstrate that restoration of NVC by SS-31 treatment in aging is associated with improvement in multiple domains of brain function, including hippocampal-dependent memory functions (Figure 3) . Previously, we found that restoration of NVC responses in aged mice by treatment with resveratrol (Toth et al., 2014 ) is also associated with marked improvement in cognitive function (Oomen et al., 2009) . It is significant that resveratrol is a potent inhibitor of mtROS production in endothelial cells (Ungvari et al., 2009) . Human studies show that procedural motor learning is affected by NVC responses (Grafton, Woods & Tyszka, 1994) and becomes significantly impaired during aging. It is thus significant that SS-31 treatment rescues motor skill learning in aged mice (Figure 4 ). Age-related deficiencies in NVC responses in human patients have been also linked to gait abnormalities (Sorond et al., 2011) . Recent studies also show that in a mouse model of radiation-induced accelerated brain aging (Ungvari et al., 2017) impaired NVC also predicts gait abnormalities. The present study identified systematic differences between young and aged mouse gait using PCA. However, rescue of NVC responses by SS-31 treatment did not reverse age-related changes in mouse gait ( Figure 4c ).
Our findings have important clinical relevance. In humans, SS-31 (elamipretide) is well tolerated with no reports of significant side effects (Szeto, 2014) and its potential to exert renoprotective and cardioprotective effects is currently being evaluated in clinical trials (Szeto, 2014) . Thus, future clinical trials with SS-31 in elderly patients are feasible, which would allow its potential in improving cerebromicrovascular and cognitive outcomes to be evaluated.
Importantly, NVC is also compromised both in patients with Alzheimer's disease (AD) and in animal models of AD, which is believed to trigger and/or exacerbate cognitive decline (Tarantini et al., 2016) . Further, the mitochondria-targeted antioxidant MitoQ was shown to prevent cognitive decline in mouse models of AD 
| EXPERIMEN TAL PROCED URES
Materials, experimental procedures, and statistical analyses are described in detail in the Data S1.
| Animals, SS-31 treatment
Young (3 months, n = 30) and aged (24 months, n = 40) male C57BL/6 mice were used. Mice in the aged cohort were assigned to two groups (n = 20 each group). One group of the aged mice was injected daily with SS-31 (elamipretide; also known as MTP-131 or Bendavia, 10 mg Kg
, for 10 days). This dosage of SS-31 has been shown to exert potent cardioprotective effects (Dai et al., 2011 
| Behavioral studies
After the treatment period, behavioral tasks were performed to characterize the effect of SS-31 treatment on learning and memory, sensory-motor function, gait and locomotion (n = 20 in each group).
| Radial-arm water maze testing
Spatial memory and long-term memory in each group of mice was tested using the radial-arm water maze as described (Ungvari et al., 2017) .
| Rotarod, motor skill learning
Motor coordination was assessed using the rotarod as described . Analysis of day-to-day changes in performance on the accelerating rotarod test was used to evaluate the motor skill learning. The grid hanging test was also used to evaluate balance and motor function. A grip strength test was used to measure the maximal muscle strength of forelimbs of the mice.
| Analysis of gait function
To determine how aging and SS-31 treatment affect gait coordination, we tested the animals using an automated computer-assisted method (CatWalk; Noldus Information Technology Inc. Leesburg, VA, USA) as described Toth, Tarantini, Springo et al., 2015) .
| Measurement of neurovascular coupling responses
After behavioral testing, mice in each group were anesthetized with isoflurane (4% induction and 1% maintenance), endotracheally intubated, and ventilated. Neurovascular coupling responses were assessed by measuring changes in cerebral blood flow above the left TARANTINI ET AL.
| 9 of 12 barrel cortex using laser speckle contrast imaging in response to contralateral whisker stimulation (Toth et al., 2014; Toth, Tarantini, Ashpole et al., 2015; Toth, Tarantini, Davila et al., 2015) . In a separate cohort of mice, the role of NO mediation in NVC responses was tested. In brief, in anesthetized, intubated and ventilated mice
equipped with an open cranial window, changes in CBF were assessed above the left barrel cortex using a laser Doppler probe in response to electric stimulation of the contralateral whisker pad, as described Toth et al., 2014; Toth, Tarantini, Ashpole et al., 2015) . Changes in CBF were averaged and expressed as percent (%) increase from the baseline value. To assess the role of NO mediation, CBF responses to whisker stimulation were repeated in the presence of the nitric oxide synthase inhibitor N x -Nitro-L-arginine methyl ester (L-NAME; 3 9 10 À4 M, 20 min).
| Assessment of endothelial NO-mediated vasodilation in isolated cerebral vessels
To assess the specific effect of SS-31 treatment on endothelial NO mediation, isolated segments of the middle cerebral arteries were cannulated and pressurized, as reported (Springo et al., 2015; Toth et al., 2013) . Dilations to acetylcholine (10
À8
-10 À5 M) and ATP (10 À7 M) (administered in the bath) were obtained in the absence and presence of L-NAME (3 9 10 À4 M, for 30 min). To assess endothelium-independent vasodilation, responses to the NO donor sodium nitroprusside (SNP, 10 À7 M) were assessed. At the end of each experiment, the vessels were superfused with Ca 2+ -free Krebs' buffer containing nifedipine (10 À5 M) to achieve maximal vasodilatation.
| Quantitative real-time RT-PCR
A quantitative real-time RT-PCR technique was used to analyze mRNA expression in cortical samples using validated TaqMan probes (Applied Biosystems) and a Strategen MX3000 platform, as previously reported (Toth, Tarantini, Ashpole et al., 2015) .
4.9 | Assessment of the effect of in vitro treatment with SS-31 on age-related increases in mtROS production in cultured cerebromicrovascular endothelial cells
To confirm the direct antioxidative endothelium-protective effect of SS-31 in vitro, we assessed the effect of SS-31 (10
À9
-10 À5 M, for 24 hr or 10 À5 M, for 1-24 hr) on mtROS production in cultured primary cerebromicrovascular endothelial cells (CMVECs)
derived from young and aged rats. The establishment and characterization of the cell strains used have been recently reported (Csiszar et al., 2014) . Mitochondrial O 2 À production in CMVECs was measured by flow cytometry using MitoSox Red (3 lM for 30 min), a mitochondrion-specific hydroethidine-derivative fluorescent dye, as reported.
| Seahorse respirometry
To substantiate the endothelium-protective effect of SS-31, we per- 
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